Cardiol Therapeutics Inc. (TSE:CRDL) Director Buys C$138,490.00 in Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Director David Elsley purchased 50,000 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was bought at an average price of C$2.77 per share, for a total transaction of C$138,490.00.

Cardiol Therapeutics Stock Performance

TSE:CRDL opened at C$2.79 on Thursday. The stock has a 50 day simple moving average of C$3.00 and a 200 day simple moving average of C$2.22. The stock has a market cap of C$192.51 million, a P/E ratio of -5.94 and a beta of 0.68. Cardiol Therapeutics Inc. has a 1-year low of C$0.91 and a 1-year high of C$4.26. The company has a current ratio of 2.81, a quick ratio of 6.84 and a debt-to-equity ratio of 0.83.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating on shares of Cardiol Therapeutics in a research report on Monday, April 22nd.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.